- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02236286
Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
October 29, 2018 updated by: Fay B. Horak, Oregon Health and Science University
This project will relate our new quantification of Freezing of Gait (FoG) in Parkinson's disease, using body worn inertial sensors (Aim I), with abnormalities in state-of-the-art, resting state, functional brain connectivity (Aim II), and determine the number of subjects needed for a future, randomized clinical trial to test the efficacy of our novel, Agility Boot Camp (ABC) rehabilitation intervention for FoG (Aim III).
The technological approaches to these aims are cutting edge and will allow us to develop sensitive behavioral and brain biomarkers for gait disorders in Parkinson's disease (PD) for use in future clinical trials.
Study Overview
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- VA Portland Health Care System (VAPORHCS)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 50-90 years old.
- No musculoskeletal or peripheral or central nervous system disorders (other than idiopathic Parkinson disease, iPD) that could significantly affect balance or gait .
- Capable of following directions.
- iPD subjects: United Kingdom Brain Bank criteria, i.e., bradykinesia and at least one of the following: rest tremor, muscular rigidity, and postural instability not cause by visual, vestibular, cerebellar or proprioceptive dysfunction. Unilateral onset, response to levodopa.
Exclusion Criteria:
- Inability to stand or walk for 2 min without an assistive device
- Recent changes in medication
- Excessive use of alcohol or recreational drugs,
- Contraindications to MRI scans (eg, claustrophobia, metal in body)
- Intervention subjects will be excluded if: 1) participating in a vigorous exercise program more than 2 x/week, 2) A medical condition that contraindicates exercise participation.
- Idiopathic PD subjects: Same as above and deep brain stimulation electrodes. Significant tremor that would interfere with MRI scan.
Control subjects:
- Will be matched for age and gender to iPD group.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise
Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions).
The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD.
The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
|
Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
|
Active Comparator: Chronic Disease Management Education
Subjects will also receive (cross-over) six weeks of educational classes.
The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism.
Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks.
Subject will do an additional 120 minutes of relaxation at home/week.
|
Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Freezing of Gait Index
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Quantify amount of freezing in the legs ('trembling of knees'), defined as the square of the total power in the 3-8 Hz band, divided by the square of the total power in the 0.5-3 Hz band.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the New Freezing of Gait Questionnaire (NFOGQ) score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The NFOGQ will be used to identify 'freezers' (score > 3).
It is a self-report measure that begins with the presentation of a short video to illustrate FoG during walking, turning and starting gait and then follows with questions related to frequency and duration of each type of FoG episode.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in PDQ-39 score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The Parkinson's Disease Quality of Life Questionnaire (PDQ-39) has 39 questions reflecting eight domains of quality of life (Mobility, Activities of Daily Living, Emotional well-being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort).
Each item scores from 0 (never) to 4 (always).
Subscale scores and a summary index representing the global health-related quality of life will be calculated, with higher scores representing worse quality of life.
Convergent validity is very good and discriminative validity for PD severity levels have been established.
The PDQ-39 will reflect limitations to participation in community mobility.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in Activities of Balance Confidence (ABC) Questionnaire score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
ABC questionnaire consists of 16 questions about how balance confidence limits participating in the community such as riding an escalator or walking in a crowded area, Subjects indicate their confidence from 0 - 100% in being able to complete each of the tasks.
A score of 80% indicates an average level of physical functioning for older adults.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in instrumented gait and balance measures
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Gait: Walking metrics will be collected during short (7 meter, 180° turn, 7 meter) and long (2 minutes) walks. Instrumented Brief BESTest - another variation of the BESTest (Balance Evaluation - Systems Test) that will be administered with inertial sensors to quantify the important metrics of the test. |
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in mini-BESTest score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The mini-BESTest assesses dynamic balance via a 14-item test that measure multiple domains of balance including anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in UPDRS score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The Unified Parkinson's Disease Rating Scale (UPDRS) Motor Subscale is a 10-minute assessment of motor signs related to severity of PD.
If the investigators have trouble recruiting subjects of similar severity in the 2 groups (PD Freezers and Non-Freezers, then they will use the Postural Instability and Gait Disability (PIGD) Subscore as a covariate in data analysis.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in locomotor neural network functional connectivity strength
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Changes in resting state blood oxygen level dependent neural signal synchronization between Supplementary Motor Area and Mesencephalic locomotor region across 3 time points.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Change in SCOPA-COG score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Scales for Outcomes in Parkinson's Disease-cognition (SCOPA-COG) is an instrument that was designed to assess the specific 'frontal-subcortical' cognitive deficits found in Parkinson's disease.
The scale, consisting of 10 items, covers the following domains: memory and recall (verbal recall, digit span backward, and indicate cubes), attention (counting backward, months backward), executive function (fist-edge-palm, semantic fluency, and dice), visual-spatial functions (assembly pattern), and memory (delayed recall).
The score ranges from 0-43 points with higher scores reflecting better performance.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Fay B Horak, PhD, PT, VA Portland Health Care System (VAPORHCS)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
September 1, 2018
Study Completion (Actual)
October 1, 2018
Study Registration Dates
First Submitted
September 3, 2014
First Submitted That Met QC Criteria
September 9, 2014
First Posted (Estimate)
September 10, 2014
Study Record Updates
Last Update Posted (Actual)
October 30, 2018
Last Update Submitted That Met QC Criteria
October 29, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8979
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Exercise
-
University of Kansas Medical CenterRecruiting
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of
-
University of AlbertaWomen and Children's Health Research Institute, CanadaRecruitingType 1 Diabetes | Post-menopauseCanada
-
Uskudar UniversityCompleted
-
Yuksek Ihtisas UniversityCompletedDementia | Frailty | Cognitive Function | Reaction Time | Aerobic Exercise | Balance ExerciseTurkey
-
National Taiwan Normal UniversityCompletedAging | Cognitive DeclineTaiwan
-
Wayne State UniversityUnknown